Background-Inflammatory bowel disease (IBD) has been linked to adverse cardiovascular events, but a relation to heart failure (HF) is uncertain. We investigated the IBD-associated risk of HF in a nationwide setting. Methods and Results-A total of 5 436 647 Danish citizens, with no history of IBD or HF, were included on January 1, 1997, and followed up until first hospitalization for HF, death, or December 31, 2011. Of these subjects, 23 681 developed IBD for which disease activity was determined continuously throughout the study. The risk of hospitalization for HF was estimated with a Poisson regression model adjusting for comorbidity and cardiovascular pharmacotherapy as timedependent covariates. During a mean follow-up of 11.8 years in the reference population and 6.4 years in the IBD group, hospitalization for HF occurred in 553 subjects with IBD and 171 405 in the reference population. Patients with IBD had a 37% increased risk of hospitalization for HF (incidence rate ratio, 1.37; 95% confidence interval, 1.26-1.49) compared with the reference population. IBD activity-specific analyses showed markedly increased risk of HF hospitalization during flares (incidence rate ratio, 2.54; 95% confidence interval, 2.13-3.04) and persistent activity (incidence rate ratio, 2.73; 95% confidence interval, 2.25-3.33) but not in IBD remission (incidence rate ratio, 1.04; 95% confidence interval, 0.94-1.16). Conclusions-In a nationwide cohort, IBD was associated with an increased risk of hospitalization for HF, and this risk was strongly correlated to periods of active disease. The mechanisms underlying this finding warrant further studies.
H eart failure (HF) is among the most frequent hospital discharge diagnoses of patients aged ≥65 years, constituting a considerable healthcare burden with an expected increased prevalence in the future. [1] [2] [3] Inflammatory bowel disease (IBD) is characterized by intestinal inflammation and periodical flares with increased disease activity, and along with other chronic inflammatory diseases, IBD has been linked to an increased risk of cardiovascular disease, including myocardial infarction, stroke, and atrial fibrillation. [4] [5] [6] [7] [8] [9] Research has provided evidence that inflammatory activation plays a role in the development and progression of HF, and the prothrombotic state associated with inflammation has been suggested as a causal link between IBD and atherothrombosis. [10] [11] [12] [13] [14] [15] [16] [17] In addition, intestinal inflammation in IBD, especially during flares, may contribute to the development of HF by translocation of bacterial lipopolysaccharides from the bowel to the circulatory system that elicit production of proinflammatory mediators and tissue injury including myocardial damage. 10, 11 However, whether IBD is associated with an increased risk of HF has not been explored previously. We therefore determined the IBD-associated risk of developing HF and the importance of IBD disease activity by evaluating all first-time hospitalizations for HF in a Danish nationwide cohort.
Methods

Setting and Data Sources
This is a historical cohort study using existing registries of the entire Danish population followed up from 1997 until 2011. Eligible subjects were identified by use of the Civil Person Registration system, which contains information on birth date, sex, vital status, annual taxed income, and migration status, registered according to each citizen's unique and permanent civil registration number. All contacts with the public healthcare system are based on this registration number and thus allowed us to do individual level-linkage across the nationwide hospital and drug prescription registers. 18 The National Patient Register holds information on all in-hospital contacts since 1978 and all outpatient activity since 1995. 19 
Study Subjects
The study cohort comprised all Danish citizens aged ≥18 years with no history of IBD or prior hospitalizations for HF. Eligible subjects were included on January 1, 1997, or on their 18th birthday, and followed up until first hospitalization for HF, death, or December 31, 2011 ( Figure 1 ). We identified individuals with new-onset IBD by a combined criteria of a first-time diagnosis of IBD, that is, Crohn's disease or ulcerative colitis, and a claimed prescription of IBD pharmacotherapy (Tables in the Data Supplement) within the period from  1 year before to 1 year after diagnosis. We used the latest of either the date of prescription or diagnosis as date of IBD onset, to avoid including risk time conditioned on future events, and we excluded subjects who received IBD pharmacotherapy (apart from glucocorticoids) >1 year before the date of IBD diagnosis.
IBD Activity
In patients with IBD, hospitalizations with IBD as primary diagnosis, initiation of biological anti-tumor necrosis factor treatment, and claimed prescription of glucocorticoids were used as surrogate markers for disease activity (Tables in the Data Supplement). By combined use of these markers, disease stages of remission, flare, and persistent activity were defined. Patients were defined as in remission starting 120 days after last disease activity (IBD hospitalization, anti-tumor necrosis factor treatment, or glucocorticoid prescription), and remission continued in the absence of further disease activity. Disease activity after a remission period defined a flare, which was set to 120-day duration. Likewise, the first 120 days after onset of IBD was defined as a flare. Finally, we defined periods of persistent activity, which succeeded flares if additional disease activity occurred within the 120 days from flare start ( Figure 2 ).
Study End Point
The end point for the study was first hospitalization for HF, recorded as discharge diagnosis in the National Patient Registry.
Comorbidity and Pharmacotherapy
Baseline comorbidity was registered by hospitalizations in the 5 years before study start, and baseline pharmacotherapy was defined by ≥1 dispensed prescription in the 2 years preceding study inclusion. Both comorbidity and pharmacotherapy were updated continuously throughout follow-up. We evaluated the following comorbidities: diabetes mellitus, atrial fibrillation, chronic obstructive pulmonary disease (COPD), renal disease, hypertension, vascular disease, and thromboembolism ( Table I in the Data Supplement). Pharmacotherapy included glucose-lowering agents, lipid-lowering agents, platelet inhibitors, and (for sensitivity analyses) loop diuretics ( Table II in the Data Supplement). Hypertension was defined by treatment with ≥2 of the following classes of antihypertensive drugs within a 90-day period: α-adrenergic blockers, non-loop diuretics, vasodilators, β-blockers, calcium channel blockers, and renin-angiotensin system inhibitors, as previously validated with a positive predictive value of >80%. 20 Hypertension and diabetes mellitus were defined by either drug prescriptions or hospital diagnoses, whichever came first.
Statistical Analyses
Baseline characteristics were presented as mean with SDs for continuous variables and frequencies and percentages for categorical variables. Incidence rates of hospitalization for HF were presented per 1000 person-years for subjects with and without IBD, respectively. We fitted 2 Poisson regression models to calculate incidence rate ratios (IRRs) of HF comparing the IBD group, with the reference population. 21 The primary model was adjusted for age, sex, calendaryear, income, comorbidity, and pharmacotherapy, all determined as time-dependent variables, whereas the second model solely adjusted for age, sex, and calendar-year. Two models were explored to assess the influence of comorbidities such as vascular disease, which is more prevalent in IBD, and hereby potentially acts as intermediates. Time bands were split in 1-year periods from January 1, 1997, and age was updated in each time band split. In IBD activity analyses, we categorized exposure time as flare, persistent activity, or remission. The assumption of a constant rate of examined variables within each time band was tested and confirmed by demonstrating the same results with a finer split of 6 months (not shown). Interactions were tested and found to be absent unless otherwise reported. The assumption of linearity of continuous variables was tested by demonstrating that quartiles of these variables did not add to the prognostic value of the model. For sensitivity analyses, we did a 1:5 age-and sex-matched cohort analysis where we included IBD subjects and matched controls at the time of IBD onset and followed up them until hospitalization for HF, death, or December 31, 2011. Furthermore, we changed the definition of the study end point to either a prescription of loop diuretics or an HF discharge diagnosis (as done previously), and only hospitalizations with a primary diagnosis of HF, respectively. Furthermore, we excluded patients with IBD and >1 annual hospital admission, on average, during follow-up, and we also performed analyses excluding patients with COPD to evaluate the effects of potential misclassification of flares because of pulmonary indications for glucocorticoids. Finally, we varied the assumed flare duration to 60 and 180 days compared with the 120 days used for the primary analyses to assess effects on the disease activity-dependent risk estimates. SAS version 9.2 and Stata version 11.1 were used for statistical analyses. The study was conducted and reported according to the Strengthening the Reporting of Observational Studies in Epidemiology guidelines. 22 
Ethics
Register-based studies do not require ethical approval in Denmark. Individual patients were not identifiable as the personal identification numbers were encrypted. The Danish data protection agency approved the study (reference no. 2007-58-0015, I.suite no. 00916 GEH-2010-001).
Results
From January 1, 1997, we included 5 436 647 Danish citizens, aged ≥18 years, with no history of IBD or prior hospitalizations for HF. Of these, 23 681 patients developed new-onset IBD throughout follow-up and constituted the IBD group. Mean age in the IBD group was 38.3 years compared with 40.7 years in the reference population and women comprised 53.7% and 50.7% of the IBD group and the reference population, respectively. Despite these differences, baseline comorbidity and pharmacotherapy were comparable in the 2 groups. Ulcerative colitis comprised 73.3% and Crohn's disease the remaining 26.7% of the IBD group (Table 1) . Hospitalization for HF occurred in 553 patients with IBD and 171 405 subjects from the reference population, which corresponded to crude incidence rates of 3.68 and 2.69 per 1000 person-years, respectively. The IRR of hospitalization for HF in the IBD group as compared with the reference population was 1.37 (95% confidence interval [CI], 1.26-1.49) in the fully adjusted analysis (Figure 3 ). The increased risk associated with IBD was consistent in the analysis only adjusted for age, sex, and calendar-year (IRR, 1.62; 95% CI, 1.49-1.76). In patients with IBD, flares comprised 10.4%, persistent activity 4.7%, and remission the remaining 84.9% of the follow-up (Table 2) . At the time of hospitalization for HF, 120 patients were in IBD flares, 100 patients had persistent activity, and the remaining 333 patients were in remission. This disease activity-dependent association corresponded to a 2.5-fold incidence of HF during flares (IRR, 2.54; 95% CI, 2.13-3.04) and almost 3-fold increase during persistent activity (IRR, 2.74; 95% CI, 2.25-3.33), whereas risk of hospitalization for HF in patients with IBD and remission was comparable with the reference population (IRR, 1.04; 95% CI, 0.94-1.16). In stratified analyses, no significant difference (P=0.11) was observed between patients with ulcerative colitis (IRR, 1.33; 95% CI, 1.21-1.46) and Crohn's disease (IRR, 1.57; 95% CI, 1.31-1.89).
Sensitivity Analyses
In age-and sex-matched analyses, we included 23 681 patients with IBD and 116 862 matched controls, who had 553 and 1773 hospitalizations for HF, respectively. This analysis showed an IBD-associated IRR of 1.29 (95% CI, 1.17-1.42), and IRRs of 2.19 (95% CI, 1.82-2.62) and 2.40 (95% CI, 1.96-2.95) during flares and persistent activity, respectively, and IRR of 1.02 (95% CI, 0.90-1.15) during remission. When the main 19 ). Furthermore, in an analysis where the main end point was a primary hospital discharge diagnoses of HF, the increased risk in patients with IBD persisted (IRR, 1.21; 95% CI, 1.07-1.36). The IBD-associated risk of HF hospitalization remained when we excluded patients with IBD and >1 annual hospital admission (not shown) as well as when we excluded patients with COPD (IRR, 1.23; 95% CI, 1.11-1.39), with a similar activity-dependent increased incidence in flares (IRR, 2.03; 95% CI, 1.59-2.58) and persistent activity (IRR, 1.90; 95% CI, 1.43-2.54). Finally, when we increased flare duration to 180 days, risk estimates were only marginally reduced during flares (IRR, 2.44; 95% CI, 2.07-2.88), persistent activity (IRR, 2.45; 95% CI, 2.03-2.96), and remission (IRR, 1.01; 95% CI, 0.90-1.13), whereas a shortened duration of a flare to 60 days leads to increased risk estimates during flares (IRR, 2.90; 95% CI, 2.41-3.48) and persistent activity (IRR, 3.16; 95% CI, 2.41-4.16).
Discussion
In this nationwide cohort study, we found a significantly increased risk of first HF hospitalization in patients with IBD. Importantly, we demonstrated a 2.5-fold increased risk in active stages of IBD (flares and persistent activity), whereas risk during remission periods was comparable with the reference population. The increased risk in patients with IBD was more pronounced in analyses solely adjusted for age and sex but was not considerably changed in analyses that included time-dependent adjustments for pharmacotherapy and comorbidity, that is, including effects of potential mediators of HF, such as ischemic heart disease and atrial fibrillation. Furthermore, the increased risk was consistent in sensitivity analyses with modified HF end points and exclusion of patients with COPD, respectively.
The present study is the first to demonstrate an association between IBD, in particular active stages of the disease, and hospitalization for HF. Inflammation is likely to be an important mechanism underlying this finding and inflammatory activation may play a central role in the pathogenesis of HF through an array of mechanisms that can contribute to, for example, myocardial injury and endothelial dysfunction. 10, 12, 13 Furthermore, inflammation also contributes to a prothrombotic state and even low-grade systemic inflammation is associated with increased risk of atherothrombotic events. 14, 17, 22, 23 IBD is characterized by inappropriate immune-mediated intestinal and systemic inflammatory activity, but other mechanisms that can increase the risk of HF in patients with IBD might be considered as well. 4, 5 In this regard, the well-known high prevalence of anemia, as well as the increased use of glucocorticoids, and susceptibility to surgical interventions and infections during IBD flares should be considered. The role of glucocorticoids in cardiovascular disease remains controversial, but these agents may, for example, diminish myocardial recovery from ischemic injury by inhibition of angiogenesis and enhancement of tissue fibrosis, which may contribute to the development of HF. 24, 25 However, in a large cohort of patients with rheumatoid arthritis, glucocorticoids were not associated with an increased risk of HF, which indicates that in this regard, their beneficial anti-inflammatory effects counterbalance adverse effects. 26 Of interest, biological antitumor necrosis factor treatment, which is used frequently in patients with IBD, was recently found not to be associated with increased risk of HF in patients with rheumatoid arthritis and in patients with chronic HF, these agents have failed to show any clinical efficacy, probably because, in part, of the well-known redundancy of inflammatory pathways and the overall complexity of HF pathogenesis. [27] [28] [29] [30] 
Strengths and Limitations
The main strength of our study was the large unselected nationwide population, and the extensive information on comorbidity and pharmacotherapy, which included only dispensed medication, that is, avoidance of recall bias. The high validity of the diagnostic coding for IBD was further strengthened by our criteria for initiation of IBD pharmacotherapy. 31 To address differences in the distribution of age and sex between patients with IBD and the reference population, we performed a matched analysis, which yielded similar IBD-associated risk estimates and hereby supported the findings from our primary analysis. The diagnostic coding of HF in the Danish registries holds a high specificity of 99% but similar to the EuroHeart Failure survey program, the sensitivity of the HF diagnosis was low (30%-50%). 32, 33 The low sensitivity of the HF diagnosis made our study more susceptible to surveillance bias, that is, subjects with IBD because of more frequent healthcare contacts are more likely to be diagnosed with HF or diagnosed at an earlier stage. This risk was particularly present during active stages of IBD, and we cannot refute that surveillance bias led to overestimation of risk of HF during IBD flares. However, to counter this critical issue, we did sensitivity analyses with the use of a combined end point of loop diuretics and HF diagnosis (to increase the sensitivity of the HF end point) and found similar results. The increased risk of hospitalization for HF persisted in an analysis with the end point restricted to primary hospitalizations for HF, as well as in an analysis where we excluded patients with IBD with >1 annual hospital visit, on average, during follow-up. Major limitations include the lack of clinical information on individual patient characteristics, including the anatomic localization and extent of IBD. Furthermore, we based the estimation of IBD disease activity on medical treatment and admissions, rather than on clinical criteria and inflammatory biomarkers, and because we used IBD treatment to establish disease activity, it is possible that systemic IBD treatment, for example, with glucocorticoids, may have contributed to the increased risk of HF during periods of IBD activity. We also lacked information on important cardiovascular risk factors including left ventricular function, obesity, physical activity, blood pressure, and smoking although some of these unmeasured confounders were adjusted for, in part, by use of time-dependent surrogates including statins for hyperlipidemia, antihypertensive treatment for hypertension, and COPD for smoking. The flare duration of 120 days was arbitrarily defined although this analysis strategy has been used previously by us and others, and we found comparable results in analyses with use of flare durations of 60 and 180 days, respectively. 16, 34, 35 
Conclusions
In a nationwide cohort, IBD was associated with an increased risk of hospitalization for HF, and this risk was strongly correlated to periods of active disease. The mechanisms underlying this finding warrant further studies.
